ProCE Banner Activity

Dupilumab for Erythrodermic AD: Results From a Pooled Subgroup Analysis

Slideset Download
Conference Coverage
Dupilumab monotherapy or with concurrent TCS shown to significantly improve signs, symptoms, and quality of life in patients with erythrodermic AD in multiple randomized, placebo-controlled, double-blinded trials.

Released: July 27, 2020

Expiration: July 26, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by educational grants from

AbbVie Inc.

Pfizer, Inc.